This is a big deal because it will also relax strategies globally and hopefully make treatment of patients more flexible and patient cantered.

CONGRESS | #EHA2025 | PRESENTATION Amitkumar Mehta @Lymphoma_MD @ONealCancerUAB presented findings from the dose-finding phase of the LuminICE-203 phase II study (NCT05883449) assessing acimtamig in combination with AlloNK in patients with R/R classical Hodgkin #lymphoma (N=24).

Agree. @ASCO This is concerning. 👇

Let me tell you why this article is dishonest For 20 years people have been saying that the patients on FDA registration studies are younger and healthier than average Americans. When you go from trial to clinic, the toxicity of drugs gets bigger, the efficacy gets smaller. For

Wow: Tafasitamab significantly improved outcomes when combined with R-Len in patients with relapsed follicular lymphoma. A new standard of care? Excellent presentation by Dr Sehn of InMind. #ASH24 #lymsm

Amitkumar Mehta, MD, (@Lymphoma_MD) of @ONealCancerUAB discussed the study design of the LOTIS-2 trial and adverse events related to loncastuximab tesirine in #DLBCL. #LYMSM https://t.co/VChxidJBcy

Atlanta airport is jam-packed. Mothers w/ small children on the floor in the terminal. Line for customer service is 1/2 mile long. No rental cars. Few hotel options. People’ve been stuck here 3 days. If there weren’t bigger national news- @Delta CEO would be dragged to testify.

Delta has completely dropped the ball on this. My family and I have been stranded at Atlanta airport for 4 days now. 0 car rentals 0 hotels (was able to get one through a rewards program 25 minutes from the airport for tonight) 0 available flights 4-5 hours in line to even

Exciting data just out @TheLancet CD22-targeted CAR T-cells in pts w DLBCL relapsed post CD19-CAR T 38 pts ORR 68% CRR 53% mDOR 27.8 months among responders https://t.co/xXUq1E6FrX #lymsm #TCellRx

Just out @NatureMedicine meta-analysis >7600 CAR T pts led by @DavidCdSMD & @KRejeski - Non-relapse mortality post CAR-T = 6.8% - highest w ciltacel (15%) & brexucel (10.6%) - axicel (7%) > tisa-/lisocel (4%) for LBCL - 51% of NRM deaths from infection https://t.co/8X9saqQa7d

Our new paper in @NEJM examines the widespread acquisitions of medical practices by UnitedHealth, Humana, Cigna, and other insurers—what’s driving this trend and what are its implications for patients and clinicians? 1/x

Young Oncologists/Hematologists Scared of Academia’s Demands: Expert Speaks Out

𝗖.𝗛.𝗔.𝗠.𝗣.𝗜.𝗢.𝗡.𝗦 🏆 #TeamIndia 🇮🇳 HAVE DONE IT! 🔝👏 ICC Men's T20 World Cup 2024 Champions 😍 #T20WorldCup | #SAvIND

📸 Frame This! WE HAVE DONE IT! 👏 🏆 #T20WorldCup | #TeamIndia | #SAvIND | @ImRo45

Thriller !! What a game…

Medical Stories - DLBCL: Karen's Story Story of Courage, Faith, Fight, Perseverance, Family, Love, Support.... https://t.co/bB7BXBFDAJ via @YouTube @ONealCancerUAB @UABNews @uabmedicine

Tune in to this #MedTableTalk episode to hear insights from @LNastoupilMD, @Lymphoma_MD & @DrLaCasce on current unmet needs in NHL patients & the relevance of new & emerging treatment modalities, & learn practical strategies for differentiating T-cell mediated treatments,

Sharing here my latest editorial in @ASHClinicalNews, addressing our flawed MOC system in hematology/oncology:

@Lymphoma_MD of @ONealCancerUAB discussed what regimens are available for patients who progressed after 2 prior lines of therapy for #DLBCL and what tolerability concerns there are for these regimens. #lymsm https://t.co/QccHOc0sk1

Just out in @JAMA_current, I describe what is known and not known about CAR-T cells turning into T Cell Lymphomas. This safety signal, while rare, has implications for ongoing trials & cell therapy reg. A balanced perspective on a new safety alert 🔽 https://t.co/UuyiMZNx1H